Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital, London, SE] 9RT, UK. Summary Two hundred and twenty patients with progressive advanced breast cancer were given primary endocrine treatment (PET) according to menstrual status. Pre-menopausal patients received ovarian irradiation (0) and post-menopausal tamoxifen 10mg bd (T). Patients were randomised to receive either no additional treatment or prednisolone 5mg bd (P). Similar results were observed in each menstrual subgroup. In 194 evaluable patients, the response to PET + P was 49% and to PET alone 30% (P<0.01). P increased the median duration of response from 9 to 14 months (P<0.002) and the median time to disease progression from 5 to 9 months (P<0.001). Response to P after 0 or T alone occurred in only 2/62 (3%). Median survival in patients randomised to receive P at the outset of PET was prolonged by 4 months (P<0.05). The addition of P significantly improves the response to 0 or T in the treatment of advanced breast cancer.
For some years the preferred primary endocrine treatment for metastatic breast cancer has been ovarian ablation for pre-menopausal, and tamoxifen for post-menopausal, patients. Corticosteroids also have activity against breast cancer (Minton et al., 1981) but the mechanism of action is not known for certain. It may be mediated by suppression of adrenal sex hormones and also have a direct action on cancer cells. When prednisolone was added to adjuvant ovarian irradiation after mastectomy for early breast cancer, it led to a significant reduction in recurrence rate and improved survival (Meakin et al., 1979) .
These observations led to a trial in this Unit to assess the contribution of prednisolone to the primary endocrine treatment of advanced breast cancer . Premenopausal patients with metastatic breast cancer were randomised to receive ovarian irradiation either alone or in combination with prednisolone, while post-menopausal patients received tamoxifen either alone or with prednisolone. The corticosteroid significantly improved the response frequency to primary endocrine treatment and, in postmenopausal patients, survival was prolonged. It was unclear from this trial whether using prednisolone sequentially, after tamoxifen alone, could have achieved similar results. A further observation was that prednisolone appeared to prevent the occurrence of hypercalcaemia and tumour 'flare' sometimes seen with tamoxifen alone. In that trial, the response to tamoxifen alone was unexpectedly low at 17% and the conclusion that prednisolone significantly improved the response frequency was only tentative. Accordingly, another trial was established to study further the contribution of prednisolone to primary endocrine treatment. This trial, in which the addition of prednisolone after failure of primary endocrine treatment alone is also studied, is reported here.
Patients and methods

Patients
Eligible patients had progressively locally recurrent and/or metastatic breast cancer, confirmed histologically and not controllable by local treatment. The disease was evaluable according to UICC criteria (Hayward et al., 1977 (Hayward et al., 1977 Other 0 1 2 4 ment (O + P and T + P) or given sequentially on disease progression (O-+P and T-.P). The numbers of patients in each of the response categories for primary endocrine treatment (O or T) with or without prednisolone (P) is shown in Table IV . In premenopausal patients, the response to 0 is increased by the addition of P (27% vs. 63%; 0.02<P<0.05). Moreover, the median duration of response is increased from 9 to 20 months (P=0.02) and the median time to disease progression from 4 to 14 months (P=0.006). In post-menopausal patients, similar trends were observed. Response frequency to T alone was 31 % and to T + P 46% (0.05 < P < 0.l1) while prednisolone significantly increased both the median duration of response (10 vs. 14 months; P=0.02) and the median time to disease progression (4 vs. 8 months, P = 0.02).
Because of the identical clinical objectives of primary endocrine treatment and the similarity of effects in pre-and post-menopausal patients, the above results have been combined. Primary endocrine treatment with prednisolone (O+ P and T + P) gives a response frequency of 49/101 (49%), while without prenidosolone (O and T) it is 28/93 (30%) (P<0.01). The median duration of response in responding patients was 9 months for primary endocrine therapy alone compared to 14 months when combined with prednisolone (P<0.002; Figure 1 ) and the median times to disease progression for patients in these groups were 5 and 9 months respectively (P <0.001; Figure 2 ).
The objective regressions at each site of assessable disease are shown in Table V The median survival of patients randomised to receive prednisolone at the outset of primary endocrine treatment was significantly increased from 17 to 21 months (P<0.05; Figure 3 ). This effect was statistically significant in premenopausal patients (17 vs. 66 months; P=0.04), but not in post-menopausal (17.5 vs. 21 months, P=0.3).
Primary endocrine treatment either with or without prednisolone was very well tolerated and any side-effects were mild. Those side-effects probably attributable to treatment are summarised in Table VII . Weight gain only gave rise to complaints when prednisolone was prescribed and affected 15% of such patients. Interestingly, hot flushes were more common in the presence of prednisolone suggesting that this agent enhances the anti-oestrogenic effect of primary endocrine treatment. The incidence of tumour 'flare' and hypercalcaemia due to tamoxifen was the same whether or not prednisolone was given. Prednisolone was added in 3 patients who developed hypercalcaemia on tamoxifen alone. Months Figure 3 Survival from start of primary endocrine treatment with prednisolone; -----without prednisolone; P<0.05). has been observed in the complete absence of oestrogen, suggesting the possibility of receptor mediated anti-growth factor activity (Vignon et al., 1987) . Tamoxifen has also been shown to induce breast cancer cells to secrete transforming growth factor-beta which inhibits cell growth (Knabbe et al., 1987) . Such mechanisms could underly the observed efficacy of tamoxifen as adjuvant treatment in oestrogen receptor negative tumours (Wilson et al., 1985) . Nevertheless, in the palliation of advanced breast cancer, response to tamoxifen is uncommon with receptor negative tumours and rare in non-hormone-dependent cancers (Jackson & Lowery, 1987) . Hence the prime objective of endocrine treatment for advanced breast cancer still seems to be a lowering of the tumour's oestrogen status which currently is best achieved by ovarian ablation in pre-menopausal and tamoxifen in post-menopausal patients. These treatments give similar results and combining these menstrual subsets as primary endocrine treatment in this trial was considered valid.
The results reaffirm those of the previous trial and show that the addition of prednisolone to primary endocrine treatment significantly increases the response frequency from an expected 30% to 49%. The duration of response and survival are also increased and particularly significant in pre-menopausal patients. The response to prednisolone after failure of primary endocrine treatment alone was poor. Response to aminoglutethimide as secondary endocrine treatment was lower than expected, but the gain achieved by combining prednisolone with initial endocrine therapy is not outweighed as shown by the survival data. Unlike the previous trial, prednisolone did not prevent hypercalcaemia or tumour 'flare'.
The mechanism of action of prednisolone is uncertain, but the larger number of patients experiencing hot flushes when this agent was used suggests that it acts, at least in part, by enhancing the anti-oestrogenic effect of treatment. In the previous trial, it was shown that prednisolone had a marked, and expected, inhibitory effect on serum dehydroepiandrosterone sulphate levels and it also marginally reduced the levels of serum oestradiol in post-menopausal women receiving tamoxifen (Blackburn et al., 1984) . Prednisolone had no effect on the serum levels of luteinising hormone, follicular stimulating hormone or prolactin.
Because of the recent interest in the role of free-oestradiol in the aetiology and clinical course of breast cancer and its availability reflected in serum levels of sex hormone binding globulin (SHBG), SHGB levels in the stored sera of patients in the previous trial have been studied (Wang et al., 1988) . In pre-menopausal patients, prednisolone had no effect on the reduction in SHGB levels seen after ovarian ablation. In post-menopausal patients, tamoxifen led to a rapid rise in SHBG levels, but this was markedly dampened by prednisolone. Hence, although treatment by ovarian ablation and tamoxifen is designed to reduce oestrogen status in women with metastatic breast cancer, the action of prednisolone on SHBG would not appear to contribute to this effect.
Two clinical trials have now shown that prednisolone improves the response to primary endocrine treatment and this is achieved without significant side effects. The mechanism of action is not known, but is probably complex involving effects on both oestrogen status and directly on the cancer cell. The optimal dose of prednisolone is not known, but higher doses than used here would probably lead to an unacceptable incidence of adverse effects. We now routinely prescribe prednisolone with ovarian ablation in premenopausal, and tamoxifen in post-menopausal, patients for the treatment of metastatic breast cancer, provided that there are no contra-indications to corticosteroids.
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